CHAPEL HILL, N.C. - iOrganBio, an innovator in intelligent cell manufacturing, today announced the appointment of Jessica Owens to its Board of Directors. Owens brings over 20 years of company-building and investing experience, including co-founding GRAIL, which raised over $1 billion and formed partnerships with Bristol Myers Squibb, Merck, and Johnson & Johnson, and serving as co-founder and General Partner at Initiate Ventures.
iOrganBio is redefining how human cells are engineered and reliably produced at scale for research and therapeutic applications, including FDA-aligned New Approach Methodologies (NAMs). The company's CellForge platform uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles. At the core of the platform is the functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type.
Owens' appointment is expected to be instrumental as iOrganBio scales CellForge, expands partnerships, and advances AI-driven cell manufacturing. According to the company, her counsel will be invaluable in improving predictability and scalability from model development to cell therapies.
For more information, visit iOrgan.Bio or follow on LinkedIn.
The appointment underscores the growing importance of AI and life sciences expertise in the cell therapy manufacturing space. iOrganBio is based at BioLabs in Chapel Hill, NC.
